Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evixapodlin in advanced solid tumors
NCT04049617Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- Aug 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of evixapodlin in solid tumor (advanced stage) (9 arms), sponsored by Gilead Sciences. Primary endpoint: Number of Participants Experiencing Dose Limiting Toxicities. Started Aug 2019; status: terminated.
02
Drugs
evixapodlin
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04049617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049617.